The CCK-B antagonist LY288513 blocks diazepam-withdrawal-induced increases in auditory startle response.
Rasmussen
K
K
Lilly Research Labs, Eli Lilly & Co., Indianapolis, Indiana 46285.
Helton
D R
DR
Berger
J E
JE
Scearce
E
E
D000161:Acoustic Stimulation; D000818:Animals; D002766:Cholecystokinin / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D003975:Diazepam / Q000633:toxicity*; D008297:Male; D011720:Pyrazoles; D051381:Rats; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*; D013216:Reflex, Startle / Q000187:drug effects* / Q000502:physiology; D013375:Substance Withdrawal Syndrome; D013997:Time Factors
D011720:Pyrazoles; D011949:Receptors, Cholecystokinin; C074681:1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone; D002766:Cholecystokinin; D003975:Diazepam